Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization
Crossref DOI link: https://doi.org/10.1038/s41598-023-30146-5
Published Online: 2023-02-24
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Matsumoto, Hidetaka
Hoshino, Junki
Nakamura, Kosuke
Akiyama, Hideo
Text and Data Mining valid from 2023-02-24
Version of Record valid from 2023-02-24
Article History
Received: 21 December 2022
Accepted: 16 February 2023
First Online: 24 February 2023
Competing interests
: The authors declare no competing interests.